HIV and antiretroviral therapy: Lipid abnormalities and associated cardiovascular risk in HIV-infected patients
HIV and antiretroviral therapy: Lipid abnormalities and associated cardiovascular risk in HIV-infected patients
复制标题
DOI：
10.1097/qai.0b013e318186519c
复制
发表时间：
2008-09-01
影响因子：
3.6
通讯作者：
Kotler, Donald P.
中科院分区：
文献类型：
--
作者：
Kotler, Donald P.
已经证明，接受高效抗逆转录病毒治疗的患者发生代谢异常的风险增加，包括血清甘油三酯和低密度脂蛋白胆固醇水平升高以及高密度脂蛋白胆固醇水平降低。这种血脂异常与代谢综合征中所见的相似，引起人们的关注，即高效抗逆转录病毒治疗也可能增加心血管并发症的风险。本文综述了 HIV 感染和高效抗逆转录病毒治疗的不同成分对血脂异常的影响，以及这些异常在增加 HIV 感染患者心血管疾病风险中的作用；还考虑了管理这些风险的治疗策略。
It has been demonstrated that patients on highly active antiretroviral therapy are at increased risk for developing metabolic abnormalities that include elevated levels of serum triglycerides and low-density lipoprotein cholesterol and reduced levels of high-density lipoprotein cholesterol. This dyslipidemia is similar to that seen in the metabolic syndrome, raising the concern that highly active antiretroviral therapy also potentially increases the risk for cardiovascular complications. This paper reviews the contribution of both HIV infection and the different components of highly active antiretroviral therapy to dyslipidemia and the role of these abnormalities toward increasing the risk of cardiovascular disease in HIV-infected patients; therapeutic strategies to manage these risks are also considered.